MAYO CLINIC
LABORATORIES

Dear Colleague,

Thank you for trusting Mayo Clinic Laboratories with your autoimmune neurology testing. On June 1, Mayo Clinic Laboratories' traditional paraneoplastic testing on serum and cerebrospinal fluid (Mayo IDs: PAVAL and PAC1) will become obsolete.

This transition reflects the advancements that have been made in the space of autoimmune neurology diagnosis. Years ago, my colleagues at Mayo Clinic and I recognized that the rapid increase in novel antibody biomarkers made a single, all-encompassing evaluation less effective. In addition, some of the new antibodies being discovered had lower paraneoplastic significance than others.

In the place of a single paraneoplastic evaluation, we developed a neurological phenotype-specific approach to autoimmune neurology testing, which has been used exclusively by Mayo Clinic physicians since 2022. Our evaluations include both autoimmune/non-paraneoplastic and paraneoplastic antibodies for any given phenotype.

This approach:

- Provides a comprehensive evaluation of a patient's condition by ensuring all antibodies relevant to a patient's phenotype are included.
- Avoids false-positive results, as antibodies that aren't clinically significant for a phenotype are not included.

We have created several resources to help guide test ordering in the phenotype-specific approach, which can be accessed at this link or by scanning the code below. I would be happy to discuss this testing with you in greater detail. Please reach out to me directly if you have any questions.

Andrew McKeon, M.B., B.Ch., M.D.
Co-Director, Neuroimmunology Laboratory
Mayo Clinic
mckeon.andrew@mayo.edu



855-516-8404 | **+1-855-379-3115** (INTERNATIONAL) | **NEWS.MAYOCLINICLABS.COM**

SCAN to learn more

MC2775-682rev0526